✦ LIBER ✦

A Risk-Benefit Assessment of Irinotecan in Solid Tumours

✍ Scribed by Lillian L. Siu, Dr Eric K. Rowinsky

Book ID: 119925009
Publisher: Springer International Publishing AG
Year: 1998
Tongue: English
Weight: 211 KB
Volume: 18
Category: Article
ISSN: 0114-5916
DOI: 10.2165/00002018-199818060-00002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefit-Risk Assessment of Irinotecan in

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

✍ Dr Bengt Glimelius 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 146 KB

Gene therapy to activate irinotecan in s

Gene therapy to activate irinotecan in solid tumours?

📂 Article 📅 1998 🏛 Adis International Limited (now part of Wolters Kl ⚖ 150 KB

Benefit-Risk Assessment of Sunitinib in

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

✍ Nathalie Theou-Anton, Sandrine Faivre, Chantal Dreyer, Professor Eric Raymond 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 567 KB

A Benefit-Risk Assessment of Imatinib in

A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours

✍ Dominik Wolf, Holger Rumpold 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 286 KB

A Risk-Benefit Assessment of Amifostine

A Risk-Benefit Assessment of Amifostine in Cytoprotection

✍ May Mabro, Sandrine Faivre, Dr Eric Raymond 📂 Article 📅 1999 🏛 Springer International Publishing AG 🌐 English ⚖ 220 KB

A Risk-Benefit Assessment of Antileukotr

A Risk-Benefit Assessment of Antileukotrienes in Asthma

✍ Dr Lewis J. Smith 📂 Article 📅 1998 🏛 Springer International Publishing AG 🌐 English ⚖ 187 KB